---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-22-000038"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T02:01:54.309585+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BeiGene CMO Hematology Jane Huang resigns; consulting agreement through Nov 2022

## Summary
- Jane Huang, M.D., CMO Hematology, resigned effective April 3, 2022.
- Consulting agreement runs from April 3 to November 14, 2022.
- Unvested options/RSUs continue vesting until June 30, 2022; exercise period extended to 90 days after consulting ends.
- No immediate replacement for CMO Hematology announced.

## SEC filing metadata
- accession: 0001651308-22-000038
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130822000038/0001651308-22-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130822000038/bgne-20220302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-22-000038
- JSON: https://secwatch.observer/filing/0001651308-22-000038.json
- Plain text: https://secwatch.observer/filing/0001651308-22-000038.txt

## Key facts
- Executive change
  Jane Huang resigned as Chief Medical Officer, Hematology at BeOne Medicines Ltd..
  - Action: resigned
  - Role: Chief Medical Officer, Hematology
  source text: On March 2, 2022, Jane Huang, M.D., Chief Medical Officer, Hematology of BeiGene, Ltd. (the “Company”), provided notice of her resignation from the Company effective April 3, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130822000038/0001651308-22-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.